All In Biotech

NDA 209964 · Amgen INC

Corlanor

Ivabradine · Oral

Priority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Aug 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Apr 22, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

95

23 Phase 3, 5 recruiting

FAERS reports

6,950

5,003 serious, 532 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 ) 1.1 Heart Failure in Adult Patients Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. 1.2 Heart Failure in Pediatric Patients Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

Mechanism: Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology ( 12.2 )] . Corlanor can also inhibit the retinal current I h . I h is involved in curtailing retinal responses to bright...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CORLANOR · IVABRADINE 5MG/5ML (1MG/ML) · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivabradine" as an intervention, any sponsor and status, largest first.

All 95 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,369
  • dyspnoea478
  • hypotension450
  • dizziness366
  • cardiac failure347
  • fatigue342
  • drug interaction332
  • drug ineffective302
  • nausea276
  • bradycardia258
  • headache251
  • chest pain206

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20085
20096
201011
201121
201242
201355
2014105
2015336
2016683
2017603
2018582
2019546
2020610
2021574
2022663
2023529
2024575
2025610
2026393

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 24, 2026

    Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28). Discontinuation of the manufacture of the drug product

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Corlanor (IVabradine HCl)

2024 spending

$40.0M

Beneficiaries

12,631

50,208 claims

Per beneficiary

$3,164

$9.67 per unit

View as table
YearSpending
2020$26,465,187
2021$31,260,406
2022$38,416,173
2023$47,305,472
2024$39,961,291

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 287 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.